

# (12) International Application Status Report

**Received at International Bureau:** 11 September 2017 (11.09.2017)

**Information valid as of:** 15 February 2018 (15.02.2018)

**Report generated on:** 19 April 2019 (19.04.2019)

**(10) Publication number:**

WO2018/045346

**(43) Publication date:**

08 March 2018 (08.03.2018)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/US2017/049958

**(22) Filing Date:**

01 September 2017 (01.09.2017)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

62/382,773 (US)

**(31) Priority date(s):**

01 September 2016 (01.09.2016)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

62/478,817 (US)

30 March 2017 (30.03.2017)

Priority document received (in compliance with PCT Rule 17.1)

62/485,188 (US)

13 April 2017 (13.04.2017)

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

**C12N 15/113** (2010.01); **A61K 9/00** (2006.01); **A61K 31/7125** (2006.01); **A61K 31/7088** (2006.01); **A61K 45/06** (2006.01); **A61K 31/713** (2006.01); **A61K 48/00** (2006.01); **C12Q 1/68** (2006.01)

**(71) Applicant(s):**

AUTOTELIC LLC [US/US]; 17870 Castleton Street Suite 250 City of Industry, California 91748 (US) *(for all designated states)*

**(72) Inventor(s):**

TRIEU, Vuong; 4003 Jim Bowie Agoura Hills, California 91301 (US)

**(74) Agent(s):**

VAKHARIA-RAO, Hema; NIXON PEABODY LLP 300 South Grand Avenue Suite 4100 Los Angeles, California 90071-3151 (US)

**(54) Title (EN):** METHODS FOR TREATING CANCER AND DETERMINING EFFICACY OF TREATMENT

**(54) Title (FR):** MÉTHODES DE TRAITEMENT DU CANCER ET DE DÉTERMINATION DE L'EFFICACITÉ D'UN TRAITEMENT

**(57) Abstract:**

**(EN):** Provided herein are methods for assessing efficacy of Trabedersen therapy in a subject in need thereof. The methods include obtaining a sample from a subject that has been treated with Trabedersen and measuring the level of cytokines in the sample, wherein a spike in the level of cytokines indicates that the treatment with Trabedersen is efficacious.

**(FR):** L'invention concerne des méthodes d'évaluation de l'efficacité d'une thérapie de Trabedersen chez un sujet en ayant besoin. Les méthodes comprennent l'obtention d'un échantillon provenant d'un sujet qui a été traité avec Trabedersen et la mesure du niveau de cytokines dans l'échantillon, un pic dans le niveau de cytokines indiquant que le traitement avec Trabedersen est efficace.

**International search report:**

Received at International Bureau: 17 November 2017 (17.11.2017) [US]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

**(81) Designated States:**

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM